HomeCompareADDXF vs PLD

ADDXF vs PLD: Dividend Comparison 2026

ADDXF yields 202.02% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADDXF wins by $120.03M in total portfolio value
10 years
ADDXF
ADDXF
● Live price
202.02%
Share price
$0.99
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$126.53M
Annual income
$64,106,411.82
Full ADDXF calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — ADDXF vs PLD

📍 ADDXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodADDXFPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ADDXF + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ADDXF pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ADDXF
Annual income on $10K today (after 15% tax)
$17,171.72/yr
After 10yr DRIP, annual income (after tax)
$54,490,450.05/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, ADDXF beats the other by $50,022,479.29/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ADDXF + PLD for your $10,000?

ADDXF: 50%PLD: 50%
100% PLD50/50100% ADDXF
Portfolio after 10yr
$66.52M
Annual income
$34,681,424.00/yr
Blended yield
52.14%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

ADDXF
No analyst data
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ADDXF buys
0
PLD buys
0
No recent congressional trades found for ADDXF or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricADDXFPLD
Forward yield202.02%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$126.53M$6.50M
Annual income after 10y$64,106,411.82$5,256,436.18
Total dividends collected$119.31M$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: ADDXF vs PLD ($10,000, DRIP)

YearADDXF PortfolioADDXF Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$30,902$20,202.02$11,255$555.24+$19.6KADDXF
2$91,409$58,344.23$13,062$1,018.59+$78.3KADDXF
3$259,102$161,293.94$15,903$1,926.67+$243.2KADDXF
4$704,521$427,281.62$20,839$3,823.32+$683.7KADDXF
5$1,839,646$1,085,809.10$30,464$8,166.08+$1.81MADDXF
6$4,618,204$2,649,782.60$52,054$19,457.30+$4.57MADDXF
7$11,158,255$6,216,776.60$109,886$54,188.93+$11.05MADDXF
8$25,977,314$14,037,980.69$304,030$186,451.18+$25.67MADDXF
9$58,339,227$30,543,501.04$1,166,125$840,813.32+$57.17MADDXF
10$126,529,384$64,106,411.82$6,504,190$5,256,436.18+$120.03MADDXF

ADDXF vs PLD: Complete Analysis 2026

ADDXFStock

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot–Marie–Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

Full ADDXF Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this ADDXF vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ADDXF vs SCHDADDXF vs JEPIADDXF vs OADDXF vs KOADDXF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.